- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings
Patent holdings for IPC class C07D 403/08
Total number of patents in this class: 329
10-year publication summary
|
19
|
28
|
27
|
17
|
20
|
14
|
28
|
24
|
18
|
5
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Achillion Pharmaceuticals, Inc. | 159 |
24 |
| Assembly Biosciences, Inc. | 100 |
14 |
| Merck Sharp & Dohme LLC | 3737 |
9 |
| Boehringer Ingelheim International GmbH | 4494 |
7 |
| Merck Patent GmbH | 5669 |
7 |
| Epizyme, Inc. | 358 |
7 |
| Incyte Corporation | 1064 |
7 |
| Janssen Pharmaceutica N.V. | 3213 |
6 |
| Gilead Sciences, Inc. | 2207 |
6 |
| F. Hoffmann-La Roche AG | 7847 |
5 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2980 |
5 |
| VisEn Medical, Inc. | 65 |
5 |
| Bristol-myers Squibb Company | 4789 |
4 |
| Cytokinetics, Inc. | 256 |
4 |
| Nippon Chemiphar Co., Ltd. | 225 |
4 |
| Taro Pharmaceuticals Inc. | 17 |
4 |
| The Regents of the University of California | 20590 |
3 |
| Vertex Pharmaceuticals Incorporated | 1589 |
3 |
| Dyomics GmbH | 19 |
3 |
| Incyte Holdings Corporation | 626 |
3 |
| Other owners | 199 |